Median treatment duration of all subjects in the study, including those without ALK-rearranged NSCLC, was 7.5 months, and the median duration of treatment was 15.4 months among those in the study with ALK-rearranged NSCLC. This evidence concerns the gene ALK and non-small cell lung carcinoma.